Stockreport

Nuvation Bio Announces Expanded Access Program in the U.S. for Taletrectinib in Advanced ROS1-positive Non-Small Cell Lung Cancer [Yahoo! Finance]

Nuvation Bio Inc. Class A  (NUVB) 
PDF Mon, February 3, 2025 at 2:00 PM GMT+1 6 min read In This Article NUVB NUVB-WS NEW YORK, February 03, 2025 BUSINESS WIRE )--Nuvation Bio Inc. (NYSE: NUVB), a [Read more]